Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment

Pharmaceutical company Lupin Ltd announced on Thursday the launch of RanluspecTM, a biosimilar of the firm’s Ranibizumab, by its commercial partner Sandoz across Europe, excluding Germany.

“The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region,” Thierry Volle, President EMEA and Emerging Markets, Lupin, said.

According to the company’s release, the development follows the European Commission's approval of RanluspecTM in vial and syringe-filled presentations.


Read more: India may open doors to multinational pharma firms for first-in-human Phase I trials

The firm, highlighting the mechanism of action of Ranibizumab, said the drug was developed to treat various types of retinal diseases.

“Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of RanluspecTM encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization,” company’s statement said.

Read more: USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'

Lupin Limited is a multinational pharmaceutical company, operating in over 100 markets. The company specialises in pharmaceutical products, including branded and generic formulations, complex generics,biotechnology products, and active pharmaceutical ingredients.